Simon D van Haren
Overview
Explore the profile of Simon D van Haren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brook B, Checkervarty A, Barman S, Sweitzer C, Bosco A, Sherman A, et al.
iScience
. 2024 Nov;
27(11):111055.
PMID: 39569372
mRNA vaccines demonstrate impaired immunogenicity and durability in vulnerable older populations. We hypothesized that human modeling and proteomics could elucidate age-specific mRNA vaccine actions. BNT162b2-stimulation changed the plasma proteome of...
2.
Martino D, Schultz N, Kaur R, van Haren S, Kresoje N, Hoch A, et al.
Clin Epigenetics
. 2024 Jul;
16(1):85.
PMID: 38961479
Background: Infants with frequent viral and bacterial respiratory infections exhibit compromised immunity to routine immunizations. They are also more likely to develop chronic respiratory diseases in later childhood. This study...
3.
Sherman A, van Haren S, Borberg E, Swank Z, Aleissa M, Tong A, et al.
Vaccine
. 2024 Jun;
42(22):126054.
PMID: 38862310
Heterologous COVID-19 vaccine boosters have not been evaluated for patients with hematological malignancies. A Novavax booster was administered for 56 individuals with hematological malignancies who had received a primary COVID-19...
4.
Thomas S, Pak J, Doss-Gollin S, Ryff K, Beijnen E, Pedersen G, et al.
J Mol Biol
. 2024 Jan;
436(4):168446.
PMID: 38242283
Adjuvants are vaccine components that can boost the type, magnitude, breadth, and durability of an immune response. We have previously demonstrated that certain adjuvant combinations can act synergistically to enhance...
5.
Zimmermann J, van Haren S, Diray-Arce J, Adriawan I, Worzner K, Krog R, et al.
NPJ Vaccines
. 2024 Jan;
9(1):13.
PMID: 38212391
No abstract available.
6.
Zimmermann J, van Haren S, Diray-Arce J, Adriawan I, Worzner K, Krog R, et al.
NPJ Vaccines
. 2023 Dec;
8(1):189.
PMID: 38135685
Class-switching to IgG2a/c in mice is a hallmark response to intracellular pathogens. T cells can promote class-switching and the predominant pathway for induction of IgG2a/c antibody responses has been suggested...
7.
Doss-Gollin S, Thomas S, Brook B, Abedi K, Lebas C, Auderset F, et al.
NPJ Vaccines
. 2023 Oct;
8(1):163.
PMID: 37884538
Adjuvants can enhance vaccine immunogenicity, but their mechanism of action is often incompletely understood, hampering rapid applicability for pandemic vaccines. Herein, we characterized the cellular and molecular activity of adjuvant...
8.
Beijnen E, Odumade O, van Haren S
Vaccines (Basel)
. 2023 Mar;
11(3).
PMID: 36992093
Clinical manifestations from primary COVID infection in children are generally less severe as compared to adults, and severe pediatric cases occur predominantly in children with underlying medical conditions. However, despite...
9.
Brook B, Fatou B, Checkervarty A, Barman S, Sweitzer C, Bosco A, et al.
Res Sq
. 2023 Jan;
PMID: 36597547
mRNA vaccines have been key to addressing the SARS-CoV-2 pandemic but have impaired immunogenicity and durability in vulnerable older populations. We evaluated the mRNA vaccine BNT162b2 in human whole blood...
10.
Sherman A, Crombie J, Cheng C, Desjardins M, Zhou G, Ometoruwa O, et al.
Open Forum Infect Dis
. 2022 Aug;
9(8):ofac417.
PMID: 36043177
Background: Patients with lymphoid malignancies are at risk for poor coronavirus disease 2019 (COVID-19)-related outcomes and have reduced vaccine-induced immune responses. Currently, a 3-dose primary regimen of mRNA vaccines is...